In India, awareness about prostate cancer remains alarmingly low, with many men avoiding screenings altogether and dismissing early warning signs until the disease has progressed. This reluctance ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

"We found that preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with PCa, highlighting its role in exacerbating disease progression and worsening survival.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...

Dr. Bill Salter, senior director of radiation oncology at the Huntsman Cancer Institute, gives a tour of the treatment room at the Sen. Orrin G. Hatch Center for Proton Therapy at the institute in ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.